



# Nasal spray immunisation: potential use against HIV and SARS-CoV-2 shown in animal models



To achieve effective immunisation and induce humoral immunity and systemic antibody responses at the entry to [mucous membrane sites](#), novel and innovative methods are constantly being tested to provide protection for individuals from emerging and existing pathogens. Such pathogens include that of the new SARS-CoV-2 virus and existing ones such as HIV. Several studies have shown that HIV, SARS-CoV-2 and other viruses, are dependent on both the systemic and [mucosal immune response](#) in order to combat infection and provide protection for the individual, with the induction of IgA and IgG.

Common immunisation techniques do not induce sufficient mucosal immunity. In a recent paper by Hartwell, et al., the researchers tested whether albumin-binding amph-vaccines would enable and enhance FcRn-mediated vaccine uptake within the nasal mucosa (Figure 1). In his paper, researchers modified protein antigens geared towards systemic and mucosal immune responses which are induced by intranasal vaccination in small and large animal models. They then assessed the level of induction of the systemic and mucosal immune response using fluorescently labelled proteins.



**Figure 1: Amph-protein conjugates exhibit enhanced persistence in the nasal mucosa and transport across the mucosal surface.** (A) Schematics illustrating (top) the ventral view of mouse upper palate and underside of top jaw, showing regions of interest (ROIs) used to quantify IVIS signals in (B) and (E), and (bottom) the sagittal view of mouse skull and nasal cavity showing approximate location of corresponding coronal cross sections used for histology in (G) and (H). (B) Representative IVIS images are shown of fluorescent signal in the nasal cavity of BALB/c mice ( $n = 3$  animals per

group) over time after intranasal administration of 5  $\mu$ g of AF647-eOD or AF647-amph-eOD mixed with 5  $\mu$ g of SMNP adjuvant. ROIs used to quantify IVIS signal are marked with dotted white oval. h, hour; d, day. (C) Quantified IVIS signals from (B) in nasal cavity over time are shown as average radiant efficiency. p, photon. Statistical significance was determined by unpaired t test at each time point. Data shown are from one representative of two independent experiments. (D) Quantified IVIS signal area under the curve (AUC; total radiance  $\times$  time) from (C) was calculated. Statistical significance was determined by an unpaired t test. (E) Representative IVIS images show vaccine uptake and retention in the nasal cavity over time after intranasal administration of 5  $\mu$ g of AF647-eOD or AF647-amph-eOD mixed with 5  $\mu$ g of SMNP adjuvant in WT C57BL/6 versus FcRn $^{-/-}$  mice (n = 3 animals per group). (F) Quantified IVIS signal from (E) is shown for the nasal cavities of WT versus FcRn $^{-/-}$  mice at 6 hours after vaccination. Statistical significance was determined by two-way ANOVA followed by Tukey's post hoc test. (G and H) Representative histology images of vaccine in nasal cavity in WT versus FcRn $^{-/-}$  mice at 6

hours are shown. Images in (H) are higher magnification views of dashed areas marked in (G). Scale bars, 1 mm (G) and 500  $\mu\text{m}$  (H). (I to K) Representative histology images of vaccine in nasal cavity in WT versus FcRn<sup>-/-</sup> mice at 24 hours and immunization. Images in (J) are higher magnification views of dashed areas noted in (I). (K) High-magnification views stained with DAPI to identify the epithelial cell barrier; white arrows denote vaccine uptake. e marks epithelium, lp marks lamina propria, and m marks mucus. Scale bars, 1 mm (I), 500  $\mu\text{m}$  (J), and 100  $\mu\text{m}$  (K). All data are presented as means  $\pm$  SEM. \* $P < 0.05$  and \*\* $P < 0.01$  (Hartwell, et al., 2022).

In this paper, they were able to show the benefits of using modified antigens such as amph-protein immunogens which showed enhanced uptake by nasal mucosa and induction of follicular helper T-cells (Tfh) and other immune responses. They also described the induction of neutralising antibodies against SARS-CoV-2 and HIV using variations of amph-protein which were conjugated with respective viral proteins.

Although this study is limited through the immunological difference that exists between animal models and humans, it highlighted the potential of intranasal delivery of amph-protein vaccines especially as we combat viruses such as HIV and SARS-CoV-2.

**Journal article: Hartwell, L. B., et al. 2022. [Intranasal vaccination with lipid-conjugated immunogens promotes antigen](#)**

[transmucosal uptake to drive mucosal and systemic immunity.](#)  
*Science Translational Medicine.*

*Summary by Stefan Botha*